Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
08 11월 2023 - 8:30PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that John Evans, chief executive officer, plans to
participate in a fireside chat during the 2023 Jefferies London
Healthcare Conference on Wednesday, November 15, 2023 at 4:30 p.m.
GMT in London.
A live webcast will be available in the investor section of the
company's website at www.beamtx.com, and will be archived for 60
days following the presentation.
About Beam TherapeuticsBeam Therapeutics
(Nasdaq: BEAM) is a biotechnology company committed to establishing
the leading, fully integrated platform for precision genetic
medicines. To achieve this vision, Beam has assembled a platform
that includes a suite of gene editing and delivery technologies and
is in the process of building internal manufacturing capabilities.
Beam’s suite of gene editing technologies is anchored by base
editing, a proprietary technology that is designed to enable
precise, predictable and efficient single base changes, at targeted
genomic sequences, without making double-stranded breaks in the
DNA. This has the potential to enable a wide range of potential
therapeutic editing strategies that Beam is using to advance a
diversified portfolio of base editing programs. Beam is a
values-driven organization committed to its people, cutting-edge
science, and a vision of providing life-long cures to patients
suffering from serious diseases.
Contacts:
Investors:Holly ManningTHRUST Strategic
Communicationsholly@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024